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Supervised and home-based physical
exercise in patients newly diagnosed with
multiple myeloma—a randomized
controlled feasibility study
Rikke Faebo Larsen1,2,3* , Mary Jarden4,5, Lisbeth Rosenbek Minet2,6,7, Ulf Christian Frølund8 and Niels Abildgaard2,9,10
Abstract
Background: The study evaluated the feasibility and safety of the exercise intervention and physical test
procedures of our ongoing randomized controlled trial, examining the effect of physical exercise in newly
diagnosed patients with multiple myeloma.
Methods: Patients are randomized 1:1 to a control group (usual care) or an intervention group (usual care and
exercise) by block randomization with stratification of planned treatment, WHO performance status, and study site.
The exercise intervention consists of eight supervised exercise sessions combined with home-based exercise over a
10-week period. Bone disease is systematically evaluated to determine limitations regarding physical testing and/or
exercise. Feasibility outcome measures were study eligibility, acceptance, and attrition, and furthermore attendance,
adherence, tolerability, and safety to the exercise intervention. Additionally, test completion, pain, and adverse
events during the physical test procedures were evaluated. Outcome assessors were blinded to allocation.
Results: Of 49 patients screened, 30 were included. The median age was 69 years, range 38–90, 77% were males,
and 67% had bone disease. Study eligibility was 82%, acceptance 75%, and attrition 20%. Attendance at supervised
exercise sessions was 92%, and adherence to supervised exercise sessions and home-based exercise sessions was
99% and 89%, respectively. No serious adverse events attributed to exercise or physical tests were reported. All
patients completed the physical tests, except for two patients, where physical test procedures were modified due
to bone disease.
Discussion: The exercise intervention and physical test procedures were feasible and safe in patients with multiple
myeloma, even in older patients with multiple myeloma and in patients with myeloma bone disease.
Trial registration: ClinicalTrials.gov. ID NCT02439112. Registered on May 7, 2015.
Keywords: Physical exercise, Multiple myeloma, Bone disease, Feasibility, Safety
Background
Physical exercise in patients with hematological cancer has
been shown to be feasible and safe and yielding benefits for
aerobic capacity, muscle strength, quality of life (QoL), psy-
chosocial wellbeing, treatment-related symptoms, fatigue,
and body composition, before, during, and after stem cell
transplantation [1–4]. However, exercise research in
hematological malignancy is rather sparse [5, 6], having
been carried out in specific hematological diagnoses such
as acute leukemia [1]. Few exercise studies have been con-
ducted in patients with multiple myeloma (MM), recently
reviewed by Gan et al. [7].
MM is a plasma cell cancer in the bone marrow that
primarily affects older adults. The incidence and preva-
lence have increased as the aging population continues
to grow, and survival has improved due to advancements
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in medical treatments [8–11]. In Europe, the incidence
of MM is 5.72 per 100,000, and the median age at diag-
nosis is 68 years [9]. At the time of diagnosis, most
patients have a symptomatic disease that requires
treatment.
Younger, fit patients (< 65–70 years) are treated with
bortezomib-based induction treatment followed by
high-dose chemotherapy with stem cell support (HDT-
SCT) [12]. Older patients or patients with comorbid
conditions receive less intensive, yet still effective treat-
ments that include the proteasome inhibitor bortezo-
mib and/or the immunomodulatory agent lenalidomide
[13–15]. Bone disease with osteopenia, pathological
fractures, and typically “punched out” lytic lesions are
hallmarks of the disease and are present in approxi-
mately 80% of the patients at the time of diagnosis and
even more during the course of the disease [16]. The
bone disease is caused by myeloma-induced increased
bone degradation by osteoclasts and inhibited the for-
mation of new bone matrix by osteoblasts [17]. Painful
bone lesions may be treated with radiation therapy, and
all patients receive intravenous bisphosphonates to re-
duce the risk of progressive bone disease, pain, and
fractures [18, 19]. Anemia is present in 70–80% of the
patients [16, 20]. Patients with MM experience more
symptoms and more severe symptoms than patients
with other hematological diseases, negatively affecting
QoL [21]. Due to the frequent and potentially serious
bone involvement, and because MM is a cancer in the
older population, the potential role of exercise needs to
be investigated separately in patients with MM.
Three randomized controlled trials [22–24] and one
single-arm pilot study [25] investigating the effect of
exercise in patients with MM have been conducted and
summarized in the review by Gan et al. [7]. The exer-
cise interventions comprised stretching, aerobic exer-
cise, and strength resistance exercises [22–25], lasted
between 18 and 26 weeks, and started either approxi-
mately 10 weeks after the start of induction [22–24] or
after HDT-SCT [25]. The studies found exercise to be
feasible and safe, whereas efficacy data showed mixed
results. However, studies that intervene at the time of
diagnosis and start of active anti-myeloma therapy are
lacking, as are studies that include older patients who
comprise the majority of patients newly diagnosed with
MM. Thus, the effectiveness of participation in exercise
programs remains unclear for patients with MM.
Gan et al.’s exercise recommendations for patients
with MM suggest that exercise should be individually
adjusted, taking the severity of the disease and the ag-
gressiveness of the treatment into consideration to pre-
vent or minimize physical deterioration [7].
In 2015, we initiated a randomized controlled trial
(RCT) to investigate the efficacy of early initiated,
individualized physical exercise intervention, combin-
ing supervised exercise sessions and home-based exer-
cise sessions and physical activity in patients newly
diagnosed with MM. The RCT is still ongoing. The
aim of the current study is to evaluate the feasibility
and safety of the exercise intervention and physical
test procedures. The feasibility of participation is eval-
uated by eligibility, acceptance, and attrition to the
study. Feasibility and safety of the exercise interven-
tion are evaluated by attendance, adherence, tolerabil-
ity, attrition, and adverse events (AEs). Feasibility and
safety of the test procedure were evaluated by com-
pletion, registration of pain, and AEs. We have used
the CONSORT 2010 statement: extension to random-
ized pilot and feasibility trials [26].
Methods
Study design, patient recruitment, and procedures
The RCT is a two-center study, with blinded outcome
assessors, carried out at the Departments of
Hematology at Zealand University Hospital, Roskilde,
and Odense University Hospital in Denmark. A total
of 102 patients will be included for efficacy evaluation
in the RCT. The primary objective of the RCT is
muscle strength of the knee extensor muscles mea-
sured by dynamometer [27], and secondary objectives
are physical measures (30 s Sit-to-Stand Test, grip
strength, Six-Minute-Walk Test), level of physical ac-
tivity (by accelerometers), QoL (EORTC-QOLQ-C30
and EORTC-QLQ-MY20), pain (Brief Pain Inventory,
short version), and bone disease (DEXA-scans and
markers of bone metabolism markers). Outcomes are
assessed after 11 weeks, 6 months, and 12 months.
Patients are consecutively screened for eligibility at
the time of diagnosis by the hematologists at each
site, based on inclusion and exclusion criteria. Pa-
tients > 18 years newly diagnosed with MM planned
for HDT-SCT or less intensive treatment regimens
are eligible. The patient must speak and understand
Danish. Exclusion criteria are spinal cord compres-
sion, unstable vertebral fracture (SINS score > 12)
[28], untreated cardiac failure or untreated cardiac
arrhythmia, severe chronic cardiac failure (NYHA 3–
4), other severe comorbidities that would not permit
physical exercise, and psychological or psychiatric dis-
orders. Informed consent is obtained from all individ-
ual participants included in the study.
The hematologist performs a systematic assessment of
the impact of bone disease to determine restrictions re-
garding physical tests or exercise. This assessment is
based on radiographs or computed tomography of the
skeleton, and captured site, size of osteolytic lesions, and
if applicable, time since fracture, moreover the degree of
pain. Bone destructions are assessed using the principles
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of Mirels´ scoring system [29]. Restrictions of not per-
forming the static knee extensor strength and 30 s Sit-
to-Stand Test is given if a fracture is detected in the
femoral bone, if the osteolysis has a size of over two-
third/involving compacta, or if the size is between one
third to two third accompanied by any kind of pain, or
finally, if there is femoral bone destruction with moder-
ate or functional pain. Restriction to test of knee exten-
sor strength is only for the affected side. The same
assessment is applied for exercise restrictions, and the
humeral bones are assessed in the same way. Further-
more, the pelvis, costae, thoracic, and lumbar spine are
assessed. Pelvis restriction is given if there is fracture or
osteolysis (> 2 cm of the acetabulum or two third of
rami). New fractures (less than 6 weeks) of the costae or
vertebral bodies will result in restrictions, or a former
fracture accompanied by any kind of pain will also lead
to restriction. Exercise restrictions followed the resist-
ance and flexibility principles by Galvão et al. [30], which
generally means that patients do not use weights in the
strengthening exercises for the involved site and move-
ments are restricted at the involved site, e.g., rotation of
the spine.
Patients are tested at baseline within 1 week after the
start of active anti-myeloma treatment. Assessment is
conducted by physiotherapists, who have received a
structured introduction to the test procedure. Hereafter,
patients are randomized 1:1 to an intervention group
(IG) or control group (CG). Block randomization and
stratification according to treatment (planned HDT-SCT
versus (vs.) non-intensive treatment), WHO perform-
ance status (PS 0–1 vs. PS ≥ 2) [31], and study site are
performed. The randomization procedure follows a ran-
dom allocation list, which is made prior to study com-
mencement. The randomization is conducted by a
project nurse who is not part of the study group, and
the randomization list is only available to the project
nurse, and thus, outcome assessors are blinded to
allocation.
This feasibility study evaluated the first 30 included
patients in the period from June 22, 2015, to June 30,
2016. This is considered as an adequate sample size be-
cause of the nature and aim of this feasibility study [32].
Control group
The CG receives usual care, which consists of written in-
formation on the importance of being physically active,
suggestions on how to remain physically active, and
ergonomic guidance on how to lift and perform transfers
properly from a lying to sitting position. Written infor-
mation is given to the patient, by a study physiotherapist
or a nurse, during the second week after the start of
treatment. Usual care could (if needed) also include a
physician-ordered rehabilitation plan, prescribing exer-
cise for the patient in the municipality, see Fig. 1.
Intervention group
In addition to usual care, the patient is instructed to do
the exercise program three times/week and to be inde-
pendently physically active for 30 min per day, the other
4 days of the week. The exercise intervention is designed
to meet the Danish recommendations for persons > 65
years and for patients with cancer including being phys-
ically active 30 min a day for at least 10 continuous mi-
nutes at moderate intensity [33, 34]. Further, at least two
times a week, the activity must be of high intensity and
include strengthening exercises and stretching [33, 34].
The Danish recommendations are in accordance with
international guidelines [35–37].
The patient receives careful instruction regarding the
exercise intervention and a booklet with a description
of the exercises. Instructions are carried out by a study
physiotherapist who received careful and structured
introduction to the exercise intervention. The exercise
program is conducted three times weekly, and it fluctu-
ates between being conducted under supervision or
unsupervised at home. Furthermore, the patient is ex-
pected to be physically active, the remaining 4 days, see
Table 1. In total, there are eight supervised exercise ses-
sions during the 10-week intervention period, starting
1 week after diagnosis, see Fig. 1. The interval between
the supervised exercise sessions varies, because the ses-
sions are planned according to the patients’ treatment
plan to minimize the number of visits to the hospital.
The patient receives an exercise diary to document ad-
herence to the intervention, and the study physiother-
apist uses the diary as a pedagogical and motivational
planning tool. Each supervised exercise session lasts for
1 h + 15 min and consists of warm-up, aerobic exercise,
strengthening exercises, and static stretching exercises,
see Table 1.
Outcome measures
Data were collected at four time points; T0: time of diag-
nosis (screening for eligibility), T1: baseline (pre-inter-
vention), Ti: during intervention (weeks 1–10) and T2:
post-intervention (weeks 11–13), see Fig. 1.
Outcomes measures were as follows:
1. Feasibility of participation at T0: eligibility,
acceptance, and attrition rates were registered as
well as reasons for non-eligibility and decline.
2. Demographic and medical data at T1: age, gender,
PS, plan of treatment, and bone disease.
3. Feasibility and safety of the intervention at Ti:
attendance, adherence, tolerability, attrition, and
AEs. The reason for and the number of time of
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Fig. 1 Overview of the randomized controlled feasibility study including intervention and physical measurements. T0; Time 0 corresponding to
time of screening. T1; Time 1 corresponding to physical tests at baseline test. T2: Time 2 corresponding to physical tests post-intervention. A-T1;
Activity-Time 1 corresponding to accelerometer measures at baseline. A-T2; Activity-Time 2 corresponding to accelerometer measures at week 4.
A-T3; Activity-Time 3 corresponding to accelerometer measures at week 7. A-T4; Activity-Time 4 corresponding to accelerometer measures post-
intervention. 1S and 2S; Supervised exercise session one or two times weekly, respectively. H1, H2, and H3; Home-based exercise session one,
two, or three times weekly, respectively. PA; Physical activity taking place the remaining 4 days, where exercise session is not conducted
Table 1 Exercise intervention; mode, intensity, duration, and progression
Mode Intensity Duration per session Progression
Exercise program 3 times/week
Warm up 10–11 RPE 5 min
Aerobic exercise 12–13 RPE 20min ↑ intensity to 14–16 RPE
Strengthening exercise 3 sets of 12–15
reps
30–45 min ↑ weight to 3 sets of 10–12 reps
Five exercises for the lower extremitiesa
Three exercises for the upper extremitiesb
One exercise for truncusc
Stretching 30 s static 5 min –
Three muscle groups of the lower extremitiesd
Physical activity 4 times/week preference of the
patient
12–13 RPE 30min at least for 10 continuous
min
14–16 RPE (is a possibility, but not a
standard)
Aerobic exercise: If not possible to do aerobic exercise for 20min on the stationary bike during the supervised session, the progression is an increase in total time
(up to 20 min)
RPE rate of perceived exertion, Reps repetitions
aKnee extension in sitting position, knee flexion in standing position, hip extension in a prone position, toe raising in standing position, and knee bent or raise
from the chair
bArm lift in frontal plane or circulation of shoulders in standing position, elbow extension in a supine position, and elbow flexion in standing or sitting position
cStatic in supine with knees bent or supine position with knee bent and lift of foot with press from the opposite hand
dFemoral muscles (standing position), hamstring muscles (standing or sitting position), and calf muscles (standing in front of the wall)
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dropouts were registered. Attendance, adherence,
tolerability, and safety of the supervised exercise
sessions were obtained by intervention logs and
documented by the study physiotherapist.
Adherence to home-based exercise sessions was
documented in an exercise diary. Safety, i.e., AEs,
during and between supervised exercise sessions
were recorded by observation (during sessions) and
questioning patients at each of the supervised
sessions. Further, patients documented AEs in their
exercise diary.
4. Feasibility and safety of physical tests at T1 and T2
and of accelerometer measurements at A-T1, A-T2,
A-T3, and A-T4. The strength of lower extremities
was measured by two tests; Static knee extension
strength test by dynamometer [23, 38, 39] and 30 s
Sit-to-Stand-Test [39, 40]. Upper body strength was
measured by grip strength, using a hand-held
dynamometer [27, 39]. Submaximal aerobic capacity
was measured by Six-Minute-Walk Test [23, 41,
42]. Feasibility was measured by completion rates
and safety by recording of pain, if any. Other AEs
were recorded by the study physiotherapist.
Statistical analysis
Descriptive statistics were conducted using simple report
data from the project database in REDCap provided by
Open Patient data Explorative Network (OPEN), Odense
University Hospital, Odense, Denmark. The analysis was
based on intention to treat. Rates of eligibility, acceptance,
attrition, attendance, and adherence are presented in
numbers and percentages, as well as completion rates of
physical tests. Furthermore, the number of patients per-
ceiving pain or AEs was recorded. Medical and demo-
graphic data were collected and presented for all included
patients and for each group separately (IG and CG).
Results
Demographics and medical characteristics
The baseline characteristics of the participants are sum-
marized in Table 2. The median age was 69 years (range
38–90), 46% of the patients were above 70 years, and
75% were men. Sixty-seven percent had bone disease,
and half of them were assessed to have restrictions for
tests or exercise. The two groups (IG vs. CG) were com-
parable in age, gender, PS, and planned treatment. Bone
disease in the intervention group was higher than in the
control group, but not in whether the bone disease led
to any restrictions regarding tests or exercise.
Feasibility and safety
Eligibility, acceptance, and attrition
Of 49 patients screened at T0, 40 met the inclusion cri-
teria (82% eligibility). Reasons for non-eligibility were
comorbidity (n = 3), spinal cord compression (n = 2), bilat-
eral involvement of the femoral bone (n = 3), and immo-
bility because of pain (n = 1). Of the 40 eligible patients,
30 accepted participation (75% acceptance rate) and ten
patients declined (25%). Reasons for the decline were lack
of energy (n = 4), not interested in exercise (n = 2), and un-
known (n = 4). Of the 30 patients included, six participants
dropped out after inclusion (20% attrition); from IG, five
out of 17 participants (29%) and from CG, one out of 13
participants (7%). From IG, two dropped out prior to
baseline test (T1) (lack of energy (n = 1), sudden impair-
ment (n = 1)), and furthermore, there was a randomization
failure in these two cases, since they were randomized be-
fore T1. One dropped out prior to the start of exercise
intervention (the patient had the possibility of receiving
anti-myeloma treatment closer to home). Two dropped
out during the intervention period (due to stroke (n = 1)
and due to experiencing exercise as being too strenuous
(n = 1)). Dropouts took place before the fourth and the
Table 2 Patient characteristics
Patient characteristics Total
N = 30
IG
n = 17
CG
n = 13
Age (years)
Mean (SD) 68 (12.2) 69 (9.7) 67 (15.3)
Median (range) 69 (38–90) 68 (48–82) 70 (38–90)
Age groups, years (n (%))
≤ 49 3 (10) 1 (6) 2 (15)
50–59 4 (13) 2 (12) 2 (15)
60–69 9 (30) 7 (41) 2 (15)
70–79 10 (33) 5 (29) 5 (38)
80–89 3 (10) 2 (12) 1 (8)
≥ 90 1 (3) 0 (0) 1 (8)
Gender (n (%))
Male 23 (77) 14 (82) 9 (69)
Female 7 (23) 3 (18) 4 (31)
WHO performance status (n (%))
0–1 25 (83) 13 (77) 12 (93)
≥ 2 5 (17) 4 (24) 1 (8)
Planned treatment (n (%))
HDT-SCTa 18 (60) 10 (59) 8 (62)
Not HDT-SCT 12 (40) 7 (41) 5 (38)
Bone disease, in general (n (%))
No 10 (33) 3 (18) 7 (54)
Yes 20 (67) 14 (82) 6 (46)
Bone disease with restriction for tests or exercise, n = 20 (n (%))
No 10 (50) 9 (64) 1 (17)
Yes 10 (50) 5 (36) 5 (83)
aHDT-SCT high-dose therapy with stem cell transplantation
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eighth sessions, respectively. From CG, one participant
dropped out because of a lack of energy to participate in
the study, see Fig. 2.
Attendance at supervised exercise sessions
In total, 12 participants out of 14 participants (86%) who
started intervention completed the full intervention, and
11 out of 12 participants (92%) attended all supervised
sessions. The one participant who did not attend all ses-
sions participated in seven out of eight sessions, and the
one session was canceled by the participant for private
reasons, see Table 3.
Adherence, tolerability, and safety
The adherence rate of the supervised exercise sessions
was 99%. Two patients discontinued one supervised
session each, due to non-serious AEs; symptoms of pain
(n = 1) and dizziness (n = 1), see Table 3. None of the
AEs were found to be related to testing or exercise. Im-
portantly, no patients experienced pathological fractures
during testing or exercise.
Adherence to home-based exercise sessions was 89%,
and 94% out of the recommended number of days with
physical activity were completed. Eighty-three percent of
the participants had complete diary registration.
All physical tests were tolerated and safe. All partici-
pants, except one, were able to complete the knee exten-
sor strength test (primary outcome), at least in one leg.
We lack information about the reason for the missed
knee extensor strength test in the one participant.
At T1 and T3, 82% and 88%, respectively, completed
the knee extensor strength test in both legs. Test
Fig. 2 Flowchart based on the CONSORT 2010 flow diagram [26]. aOne patient was tested at baseline (T1). Two patients dropped out before
performing the baseline test, which is considered as a randomization failure. bOne patient dropped out before session 4 and one before
session 8
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completion of the secondary outcomes was 100%, except
for two participants, who did not complete the 30 s SST,
see Table 4. The completeness of data from accelerome-
ters was 92–96%. We had apparatus failure (n = 2) at A-
T4, and in one case at A-T3, we were not able to detect
the reason for incomplete data. Missing data at A-T1
were unknown, and at A-T2, the participant did not
wear the accelerometer. There were no AEs, e.g., skin
irritation.
Discussion
This study examined the feasibility and safety of an early
initiated, individualized physical exercise intervention,
combining supervised exercise sessions and home-based
exercise sessions in combination with physical activity in
patients newly diagnosed with MM. Our main finding
was that the exercise intervention and physical test pro-
cedures were feasible and safe.
We succeeded to include a broad group of patients,
including older patients planned for less intensive treat-
ment than HDT-SCT. In only one former study in pa-
tients with MM in stable phase, and either off treatment
or on maintenance therapy [25], patients were included
regardless of whether they had undergone a HDT-SCT
or other chemotherapeutic treatments. However, only
8% had not undergone HDT-SCT, compared to 40% in
our study. The median age was 61 years, range 46–74
years, compared to 69 years, range 38–90 years in our
study. The median age of 69 years indicates that con-
cerning age our cohort is representative for the general
MM population.
The eligibility and acceptance rates in our study are in
accordance with results from other studies [25, 43], even
though our study started recruitment at an earlier stage
and with the inclusion of older patients. This indicates
that participants found exercise relevant at the time of
diagnosis, as well as during the recovery phase (6–14
weeks after first-line HDT-SCT) [43] and in the stable
plateau phase [25].
Forty-nine patients were screened for participation in
the study during the first year. This was fewer than ex-
pected according to the Danish MM Registry, which
about 75 patients with newly diagnosed MM should
have been diagnosed at the two departments within
1 year [44]. Thus, approximately one third of the newly
diagnosed patients with MM were not assessed for eligi-
bility. There are several possible explanations for this;
some of the most likely are disease presentation with se-
vere complications (including severe infections), need of
hemo-dialysis, and severe immobilization due to bone
pain. Another reason is that some hematologists simply
forgot to screen and offer participation to some patients.
Table 3 Adherence to the intervention and the individual components of the intervention, and adverse events
IG
n = 12*
Comments
Adherence to supervised exercise session
Patients who completed (n (%)) 11 (92%) One participant canceled one session because of the condition.
Sessions completed (n (%))a 95 (99%)
Adjustments of the exercise program
Progression of exercise program (n (%)) 4 (33%)
Regression of exercise program (n (%)) 1 (8%)
No progression or regression (n (%)) 0 (0%)
Both progression and regression (n (%)) 7 (58%)
Adherence to home-based exercise sessions (n (%))b 203 (89%)
Adherence to physical activityc 405 (94%)
Diary registration (n (%))
All weeks 10 (83%)
Some weeks 2 (17%)
No weeks 0 (−)
Adverse events (n) 2 Dizziness (n = 1), symptoms of pain (n = 1). All non-serious adverse events.
Consequences of the adverse events
None 0
Discontinuation of the supervised exercise session (n) 2
*Data is based on participants who completed the intervention for the whole intervention period (n = 12)
aOut of 96 possible sessions (eight sessions for each participant)
bOut of 228 recommended sessions based on a period of 9 weeks
cOut of 432 recommended sessions based on a period of 9 weeks
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Probably, the included patients are skewed according to
the severity of disease and have fewer complications at
diagnosis than the general MM population. Twenty-five
percent of the eligible patients declined to participate.
The time of diagnosis is a sensitive time for the patient
with a large information burden, and some patients are
anxious and have difficulty coping with their situation.
We included fewer female patients than expected, which
is not a finding supported by the literature [45].
The attrition rate in IG (29%) is within, but in the high
end of, the range that has been observed in other studies
(4%–29%) [22, 23, 25, 43]. The attrition rate in the CG
Table 4 Patients who performed the physical tests and worn accelerometers at the investigated times
Physical tests T1*
n = 28
T2#
n = 24
A-T1*
n = 28
A-T2
n = 24
A-T3
n = 24
A-T4#
n = 24
Knee extensor strength test (n (%))
Both legs tested 23 (82) 21 (88)
Only one leg tested because of bone restriction 2 (7) 2 (8)
Only one leg tested because of patient inability 0 (−) 1 (4)
Only one leg tested without explanation 2 (7) 0 (−)
Not done 1 (4) 0
Pain during testa 4 (14) 5 (21)
Adverse events 0 0
Grip strength test (n (%))
Patients who performed the test 28 (100) 24 (100)
Not done 0 (−) 0 (−)
Pain during testb 5 (18) 3 (13)
Adverse events 0 0
30 s Sit-to-Stand Test (n (%))
Patients who performed the test 26 (93) 24 (100)
Not done 2 (7) 0 (−)
Pain during testc 5 (19) 1 (4)
Adverse events 0 0
Six-Minute-Walk Test (n (%))
Patients who performed the test 28 (100) 24 (100)
Not done 0 (−) 0 (−)
Pain during testd 8 (29) 5 (21)
Adverse events 0 0
Accelerometers (n (%))
Worn, complete data 27 (96) 23 (96) 23 22
Worn, incomplete data 0 (−) 0 (−) (96) (92)
Not worn/missing 1 (4) 1 (4) 1 (4) 2 (8)
Adverse events 0 (−) 0 (−) 0 (−) 0 (−)
aPain during test of knee extensor strength test
At T1; related to equipment (n = 2), knee pain (n = 1), undescribed (n = 1) S
At T3; related to equipment (n = 2), back pain (n = 1), minor leg pain (n = 1), missing (n = 1)
bPain during test of grip strength
At T1; sternum (n = 1), clavicular (n = 2), breast muscle (n = 1), sternum and costae (n = 1)
At T3; fingers (n = 1), costae (n = 1), known pain (n = 1)
cPain during 30 s Sit-to-Stand Test
At T1; knee pain (n = 1), back pain (n = 2), scapula and sternum (n = 1), thorax (n = 1)
At T3; back pain (n = 1)
dPain during Six-Minute-Walk Test
At T1; thorax (n = 1), sternum (n = 1), scapula and sternum and right hip (n = 1), thorax and dyspnea (n = 1), toe (n = 1), missing (n = 2)
At T3; hip muscle pain (n = 1), reaction from the thigh (n = 1), back pain (n = 1), Achilles tendon (n = 1), lower extremity (n = 1)
*T1 and A-T1 correspond to the same time point (baseline)
#T2 and A-T4 correspond to the same time point (post-intervention)
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(7%) is lower than in other studies, where attrition rates
ranged from 15 to 30% [22, 23, 43]. The four-times
higher attrition rate in IG than in CG can partly be ex-
plained by randomization failure. By following a stricter
randomization procedure, we expect more equal attri-
tion rates in the larger RCT, although the intervention
itself might play a role. Thus, exercise intervention at
the time of diagnosis is feasible for most, but not all pa-
tients with MM. However, it is noteworthy that the
attendance and the adherence were relatively high. In
total, 24 out of 30 included patients (80%) were available
for analysis, which is informative for us regarding drop-
outs in the RCT.
The studies with the lowest overall attrition (regardless
of group assignment) [25, 43] took place either in the re-
covery phase or stable plateau phase. Nevertheless, attri-
tion during active anti-myeloma treatment can be
expected to be higher. The overall attrition in our study
(20%) is within the range of other studies conducted
during treatment (11–42%) [22–24, 43].
Our attendance rate to supervised exercise sessions
was higher than the rates in other studies with super-
vised sessions [25, 43]. Our more favorable attendance
rate may be because we strive to plan the sessions on
the same days as the medical visits at the hospital, con-
trary to, e.g., exercise in a physiotherapy practice [43].
Adherence to supervised exercise sessions was 99%.
Discontinuation was a minor issue, and no serious AEs
related to physical exercise or testing were registered.
Adherence to home-based exercise sessions was 89%,
which is in accordance with the adherence of 86% in an-
other study with a mixed intervention (supervised and
home-based) [25].
Importantly, we observed no pathological fractures,
even though we intervene at a very early stage. The same
safety findings were reported in other studies of exercise
in patients with MM [23–25].
The completion rates of the physical tests were high,
not least of the primary outcome (knee extensor
strength), where we succeeded to test both legs in most
participants. Our careful assessment of bone status re-
sulted in the successful inclusion of patients with bone
disease in the lower extremities, as long as there was no
restriction in one of the legs. Thus, we allow inclusion of
patients with bone disease and even patients with
assessed increased risk of fracture. Instead of excluding
these patients, we differentiate testing and exercising ac-
cording to bone disease and pain, and therefore, we were
able to carry out tests and exercise in a safe manner. In
general, other studies excluded patients with risk of
fracture [22–24], and only one study specifically defined
this risk [25]. Our bone assessment might explain the
higher rate of test completion than seen in an earlier
study, where 76% completed the isometric strength
measurement at the initial assessment, 1–2 weeks after
diagnosis [46].
All studies, except Groeneveldt et al. [25], were de-
signed by adapting the program individually at baseline
[22–25, 43] and with adjustments during the interven-
tion period, based on the patients’ exercise logs [22–25]
or by brief, individual counseling to enhance compliance
and motivation [43]. Only Groeneveldt et al. [25] had su-
pervised exercise as part of the intervention, which is
important in order to make adjustments and to enhance
compliance [7, 47]. We consider the combined exercise
intervention (supervised and home-based), a strength for
our study.
The effects of exercise on physical parameters, QoL,
and fatigue have been conflicting across earlier studies
in patients with MM. Suboptimal compliance, the timing
of the intervention, or non-optimal intensity are reasons
discussed by authors to be possible explanations for the
non-significant results [22–24, 43]. Thus, so far, the ef-
fectiveness of physical exercise in patients with MM is
unclear, which highlights the importance of our ongoing
randomized trial.
In conclusion, early initiated, individualized physical
exercise in patients with multiple myeloma is feasible
and safe, even in older patients and in patients with
bone involvement. We succeeded in including an age
representative cohort of newly diagnosed patients and in
including patients with clinical bone disease. Our on-
going randomized study will hopefully contribute im-
portantly to answer the question if early initiated
physical exercise in patients with multiple myeloma is
effective on physical function, quality of life, pain, and
bone disease.
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